It has been found in a recent report that the U. S. Food and Drug Administration has given its approval for the drug Zaltrap (ziv-afilbercept) tested in a trial for advanced metastatic colorectal cancer to be given with another medicine.

The report says that the concerns were raised on noticing that colorectal cancer was acting as the fourth highest killer of people in the United States. While some 51,690 are being expected to die this year, almost 143,460 Americans are being hoped to be diagnosed with the same.

Zaltrap is drug used for restraining the growth of tumour as it inhibits their blood supply. The medication comes under angiogenesis inhibitors, which is a class of drugs.

Though, the drug was previously also allowed for being prescribed to those patients whose cancerous tumour becomes resistant to a received oxaliplatin-based chemotherapy. Also, it was given to those who tend to develop the disease further even after getting the chemotherapy doses.

It is now being said that the drug would be prescribed in a combo. Thus, as per the findings, a FOLFIRI chemotherapy regimen has also been certified along with the drug, which is meant for adults. The regimen comprises of fluorouracil and folinic acid as well as irinotecan.